Elutia/$ELUT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Elutia
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
- Ticker
- $ELUT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 26
- Headquarters
- Gaithersburg, United States
- Website
- elutia.com
Elutia Metrics
BasicAdvanced
$41M
0.74
$1.25
-
-
Price and volume
Market cap
$41M
52-week high
$1.39
52-week low
$0.50
Average daily volume
335K
Financial strength
Current ratio
2.631
Quick ratio
1.906
Long term debt to equity
0.528
Total debt to equity
0.528
Interest coverage (TTM)
-127.85%
Profitability
EBITDA (TTM)
-22.855
Gross margin (TTM)
57.71%
Net profit margin (TTM)
400.17%
Operating margin (TTM)
-166.49%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-36.45%
Return on equity (TTM)
190.75%
Valuation
Price to earnings (TTM)
0.737
Price to revenue (TTM)
2.95
Price to book
2.66
Price to tangible book (TTM)
2.79
Growth
Revenue change (TTM)
14.83%
Earnings per share change (TTM)
-226.48%
3-year revenue growth (CAGR)
-18.87%
3-year earnings per share growth (CAGR)
-16.13%
What the Analysts think about Elutia
Analyst ratings (Buy, Hold, Sell) for Elutia stock.
Analyst projections of the future price of Elutia stock.
Elutia Financial Performance
Revenues and expenses
Elutia Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.